» Articles » PMID: 32205440

Broad and Thematic Remodeling of the Surfaceome and Glycoproteome on Isogenic Cells Transformed with Driving Proliferative Oncogenes

Overview
Specialty Science
Date 2020 Mar 25
PMID 32205440
Citations 44
Authors
Affiliations
Soon will be listed here.
Abstract

The cell surface proteome, the surfaceome, is the interface for engaging the extracellular space in normal and cancer cells. Here we apply quantitative proteomics of -linked glycoproteins to reveal how a collection of some 700 surface proteins is dramatically remodeled in an isogenic breast epithelial cell line stably expressing any of six of the most prominent proliferative oncogenes, including the receptor tyrosine kinases, EGFR and HER2, and downstream signaling partners such as KRAS, BRAF, MEK, and AKT. We find that each oncogene has somewhat different surfaceomes, but the functions of these proteins are harmonized by common biological themes including up-regulation of nutrient transporters, down-regulation of adhesion molecules and tumor suppressing phosphatases, and alteration in immune modulators. Addition of a potent MEK inhibitor that blocks MAPK signaling brings each oncogene-induced surfaceome back to a common state reflecting the strong dependence of the oncogene on the MAPK pathway to propagate signaling. Cell surface protein capture is mediated by covalent tagging of surface glycans, yet current methods do not afford sequencing of intact glycopeptides. Thus, we complement the surfaceome data with whole cell glycoproteomics enabled by a recently developed technique called activated ion electron transfer dissociation (AI-ETD). We found massive oncogene-induced changes to the glycoproteome and differential increases in complex hybrid glycans, especially for KRAS and HER2 oncogenes. Overall, these studies provide a broad systems-level view of how specific driver oncogenes remodel the surfaceome and the glycoproteome in a cell autologous fashion, and suggest possible surface targets, and combinations thereof, for drug and biomarker discovery.

Citing Articles

Chemoproteomics reveals immunogenic and tumor-associated cell surface substrates of ectokinase CK2α.

Delaveris C, Kong S, Glasgow J, Loudermilk R, Kirkemo L, Zhao F Cell Chem Biol. 2024; 31(9):1729-1739.e9.

PMID: 39178841 PMC: 11482644. DOI: 10.1016/j.chembiol.2024.07.018.


Deciphering the tumor immune microenvironment from a multidimensional omics perspective: insight into next-generation CAR-T cell immunotherapy and beyond.

Zhou Z, Wang J, Wang J, Yang S, Wang R, Zhang G Mol Cancer. 2024; 23(1):131.

PMID: 38918817 PMC: 11201788. DOI: 10.1186/s12943-024-02047-2.


Human brain glycoform coregulation network and glycan modification alterations in Alzheimer's disease.

Zhang Q, Ma C, Chin L, Pan S, Li L Sci Adv. 2024; 10(14):eadk6911.

PMID: 38579000 PMC: 10997212. DOI: 10.1126/sciadv.adk6911.


Photoproximity Labeling from Single Catalyst Sites Allows Calibration and Increased Resolution for Carbene Labeling of Protein Partners In Vitro and on Cells.

Bartholow T, Burroughs P, Elledge S, Byrnes J, Kirkemo L, Garda V ACS Cent Sci. 2024; 10(1):199-208.

PMID: 38292613 PMC: 10823516. DOI: 10.1021/acscentsci.3c01473.


Roles of glycosylation at the cancer cell surface: opportunities for large scale glycoproteomics.

Caval T, Alisson-Silva F, Schwarz F Theranostics. 2023; 13(8):2605-2615.

PMID: 37215580 PMC: 10196828. DOI: 10.7150/thno.81760.


References
1.
. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014; 511(7511):543-50. PMC: 4231481. DOI: 10.1038/nature13385. View

2.
Chames P, van Regenmortel M, Weiss E, Baty D . Therapeutic antibodies: successes, limitations and hopes for the future. Br J Pharmacol. 2009; 157(2):220-33. PMC: 2697811. DOI: 10.1111/j.1476-5381.2009.00190.x. View

3.
Fernandes B, Sagman U, Auger M, Demetrio M, Dennis J . Beta 1-6 branched oligosaccharides as a marker of tumor progression in human breast and colon neoplasia. Cancer Res. 1991; 51(2):718-23. View

4.
Martinko A, Truillet C, Julien O, Diaz J, Horlbeck M, Whiteley G . Targeting RAS-driven human cancer cells with antibodies to upregulated and essential cell-surface proteins. Elife. 2018; 7. PMC: 5796798. DOI: 10.7554/eLife.31098. View

5.
Nagarajan A, Malvi P, Wajapeyee N . Heparan Sulfate and Heparan Sulfate Proteoglycans in Cancer Initiation and Progression. Front Endocrinol (Lausanne). 2018; 9:483. PMC: 6118229. DOI: 10.3389/fendo.2018.00483. View